Zadiel Tablet 25 mg (Empagliflozin)

Adult dose

The recommended dose of this medication is once daily 10 mg in monotherapy and as add-on therapy with other blood glucose-lowering agents including insulin. When additional blood sugar control is needed and well tolerated, the dose can be increased to 25 mg once daily. When used in combination with sulfonylureas or insulin, consideration of dose reductions for those agents may be necessary to reduce the risk of hypoglycemia. This medication is administered regardless of meals, with the tablets taken whole.

This medication should not be used in certain patients. Firstly, individuals with allergic reactions to any components of this medication should not take it. Secondly, patients with type 1 diabetes or diabetic ketoacidosis should not use this medication. Thirdly, patients with severely impaired renal function or those on dialysis should also avoid this medication. Fourthly, patients with genetic lactose intolerance or lactase deficiency, and glucose-galactose malabsorption should avoid this medication. This medication should be used with caution in patients with impaired renal function, and if renal function drops below a certain level, the medication should be discontinued. Particularly, in patients with end-stage renal disease or those on dialysis, the expected effect of this medication is not anticipated, so it is not used. In patients with mild to moderate heart failure, this medication should be used with caution, while it is not recommended for patients with severe heart failure. When this medication is used in conjunction with insulin or insulin secretagogues, there is a risk of hypoglycemia, necessitating the adjustment of dosages of these medications. During treatment, side effects such as hypoglycemia, infections, increased urination, and decreased fluid volume may occur, so caution is advised. In particular, genital infections and urinary tract infections may increase, so if symptoms occur, it is crucial to consult a doctor immediately. This medication can cause severe ketoacidosis; if suspected symptoms occur, immediate treatment should be sought, and medication discontinuation should follow if necessary. Elderly patients or those at risk for fluid volume loss should be cautious of dehydration or hypotension, with regular fluid status checks being important. Pregnant women are advised to avoid this medication, and if pregnancy is confirmed, it should be discontinued immediately. Breastfeeding women are also recommended to cease nursing during the use of this medication. Children and adolescents should not use this medication as its safety and efficacy have not been established. No specific toxicity has been reported for overdose, but if abnormal symptoms occur, immediate medical attention should be sought for appropriate treatment. Lastly, this medication may interact with other drugs, so it's important to inform healthcare professionals of any other medications being taken. Finally, this medication should be stored out of reach of children, and transferring it to another container should be avoided.

Serious side effects

• Hives
• severe swelling (angioedema)
• ketoacidosis
• urinary sepsis
• pyelonephritis
• perineal necrosis

Mild side effects

Hypoglycemia, vulvovaginal candidiasis, balanitis, and other genital infections, increased urination, rash, itching, increased serum creatinine, reduced glomerular filtration rate, increased serum lipids, decreased blood pressure, dehydration, hypotension, decreased blood volume, orthostatic hypotension, increased urine output, interstitial nephritis, increased serum lipids in diagnostic tests, increased hematocrit, thirst, and hypoglycemia related to blood sugar control during driving or machine operation.

This medication must be stored in an airtight container to prevent exposure to air or moisture, and it is best kept at room temperature between 1 to 30 degrees Celsius. Therefore, it should be securely stored away from overly hot or cold places.

Appearance

Pale yellow oval film-coated tablet

Package unit

10 tablets/PTP [10 tablets/PTP×1], 30 tablets/PTP [10 tablets/PTP×3]